The Maple Ridge resident was surprised considering, as he has since learned, multiple myeloma is the second most prevalent ...

Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly diagnosed multiple myeloma.

An international study led by the Spanish National Cancer Research Centre (CNIO) and the 12 de Octubre Hospital in Madrid ...

CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with ...

(TSVT) stock lost as company with Bristol Myers Squibb (BMY) plan to discontinue enrollments in a Phase 3 trial for cancer ...

2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma.

Multiple myeloma (MM) affects white plasma in the bone marrow. Cancerous tumors can weaken the body's immune system, damage ...

(RTTNews) - 2seventy bio (TSVT) announced that the company, in partnership with study sponsor Bristol Myers Squibb, will discontinue enrollment ...

Bristol Myers Squibb said Wednesday that they are discontinuing enrollment in the Phase 3 KarMMa-9 study investigating Abecma in patients with newly diagnosed multiple myeloma. 2seventy CEO Chip Baird ...

Melbourne mum Marlo McCarthy revealed in the Herald Sun on Monday that she has been diagnosed with the same rare blood cancer ...

WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, is excited to announce the latest advancement in the WCG ClinSpheretm platform with the addition ...

The Orlando Magic will honor their late co-founder Pat Williams with a patch on their uniforms that they will wear during the ...